Search This Blog

Wednesday, February 5, 2025

Ex-Newsguard operative opens door to left doxxing Musk's young DOGE software engineers

 By Monica Showalter

What is it about NewsGuard's name popping up every time the deep state needs a favor?

A few days ago, Wired magazine's Vittoria Elliott, who until recently worked at NewsGuard, reported this:

Elon Musk’s takeover of federal government infrastructure is ongoing, and at the center of things is a coterie of engineers who are barely out of—and in at least one case, purportedly still in—college. Most have connections to Musk, and at least two have connections to Musk’s longtime associate Peter Thiel, a cofounder and chair of the analytics firm and government contractor Palantir who has long expressed opposition to democracy.

WIRED has identified six young men—all apparently between the ages of 19 and 24, according to public databases, their online presences, and other records—who have little to no government experience and are now playing critical roles in Musk’s so-called Department of Government Efficiency (DOGE) project, tasked by executive order with “modernizing Federal technology and software to maximize governmental efficiency and productivity.” The engineers all hold nebulous job titles within DOGE, and at least one appears to be working as a volunteer.

The engineers are Akash Bobba, Edward Coristine, Luke Farritor, Gautier Cole Killian, Gavin Kliger, and Ethan Shaotran. None have responded to requests for comment from WIRED. Representatives from OPM, GSA, and DOGE did not respond to requests for comment.

Should it surprise anyone that a former NewsGuard contributor has taken to harassing young DOGE engineers seeking to find ways to cut the waste, fraud and inefficiency of the U.S. government?

NewsGuard, recall, is the censorship outfit that seeks to deplatform news and commentary outlets to advertisers by creating blacklists for clients as to which sites are reliable and which sites are not. By the wildest of coincidences, conservative outlets overwhelmingly dominate the blacklists, while mainstream media sites which reported COVID falsehoods, phony Russia collusion claims about Trump, and other shibboleths of the deep state, come out with flying colors. Newsguard takes government contracts, and has always been fast to push the deep state narrative as its axis of truth.

In Elliott's story, she made a list of the Musk team and googled, or more likely used a leftist AI program, to lay out everything that was known about these young engineers to Make Them Famous.

Here are a few examples:


Bobba has attended UC Berkeley, where he was in the prestigious Management, Entrepreneurship, and Technology program. According to a copy of his now-deleted LinkedIn obtained by WIRED, Bobba was an investment engineering intern at the Bridgewater Associates hedge fund as of last spring and was previously an intern at both Meta and Palantir. He was a featured guest on a since-deleted podcast with Aman Manazir, an engineer who interviews engineers about how they landed their dream jobs, where he talked about those experiences last June.

... and ...


Coristine, as WIRED previously reported, appears to have recently graduated from high school and to have been enrolled at Northeastern University. According to a copy of his résumé obtained by WIRED, he spent three months at Neuralink, Musk’s brain-computer interface company, last summer.

Or this one:

Farritor, who per sources has a working GSA email address, is a former intern at SpaceX, Musk’s space company, and currently a Thiel Fellow after, according to his LinkedIn, dropping out of the University of Nebraska—Lincoln. While in school, he was part of an award-winning team that deciphered portions of an ancient Greek scroll.

Some have called that doxxing, but I think she's too smart for that. The Wired 'platform and power' writer didn't reveal anyone's address, phone number or email addresses. She didn't go to anyone's home and take photographs, nor did she didn't publish any information about relatives, the way former Washington Post 'tech and online culture' columnist Taylor Lorenz crudely did.

But she didn't have to. Her report opened the door to the anonymous crazed leftists on the Bluesky platform, and other outlets, to doxx the young men, and they did.

Including this stupid one:

Reddit, too:

They had their roadmap from her article (and reportedly another by a leftist editor at Mashable) and they got to work doxxing apparently right after it was published. That raises questions as to whether that was the plan.

The natural effect of doxxing, which is threats, came next:

And then what looks like the Paris mob:

It prompted this warning from an attorney general.

It all seemed to be about intimidating the DOGE workers from doing their jobs and thus, chasing them away.

It was a pretty skeezy story given that these people aren't public figures and her only argument for doing this is that they don't know anything because of their ages.

She cited their ages as proof, missing the important detail that they were hired precisely for their outside perspective and absence of conflicts of interest. Musk has since stated that they are in fact primo talent, hand picked by him for their competence, but she didn't address that.

She makes the point repeatedly in her interview with Al Jazeera here:

Which is odd coming from a Wired reporter, who would surely know that math and tech talent peaks early in life and if these guys were working six-figure jobs at elite places like Meta or any hedge fund, or at brain science company like Neuralink, they probably contributed something of very high value, doubly so for the guy who dropped out of college, which again, in tech, is not uncommon. In that field, the best ones hire based on whether one's code looks good, not what their degrees claim. 

So while we are on the topic of publishing everyone's bio, here's her bio from the Wired site:

Vittoria Elliott is a reporter for WIRED, covering platforms and power. She was previously a reporter at Rest of World, where she covered disinformation and labor in markets outside the US and Western Europe. She has worked with The New Humanitarian, Al Jazeera, and ProPublica. She is a graduate of Columbia Journalism School and, before transitioning to journalism, worked with startups in Kenya and India.

Here's the part she left out, from NewsGuard itself:

Vittoria Elliott was a Contributing Analyst for NewsGuard. In addition to her work at NewsGuard, she is a freelance Deputy News Editor at Al Jazeera English. She has conducted investigative research for ProPublica and worked as a fact-checker for Washingtonian Magazine. She was part of ProPublica’s inaugural Electionland project, monitoring the 2016 election and verifying social media posts and information in real time.

Prior to entering journalism, Elliott worked in international development and social enterprise in India, Kenya, and Ghana.

Elliott has a B.A. in Psychology and International Relations from Tufts University and a Masters from the Columbia University Graduate School of Journalism.

She wouldn't have any conflicts of interest there, what with her past work in the aid rackets, or with the foundations (Rest of the World is financed by the Ford Foundation and the Henry Luce Foundation, and ProPublica has connections with the Soros-aligned crowd), Might that make her shill for USAID with a hit job on the guys looking at its operations? That, plus the half-hidden NewsGuard past, suggests that the whole piece was a bid to hit DOGE on behalf of the deep state.

The tone of the report is problematic, too, big on using loaded words -- like coterie, nebulous, Musk's lackeys, "experts,"  etc. which tells us the young engineers used good judgment in avoiding contact with her.

Her line about Peter Thiel being against 'democracy,' taken from a 2009 essay he wrote for Cato Unbound, distorts what Thiel said about being disillusioned with politics and being inclined to work on big projects to forget about it. That's hardly the work of a "democracy" hater as she claimed.

Musk is fair game as the top decisionmaker and as a public figure.

But the little guys? Why focus on the little guys when it's Musk making the decisions? What news value does that impart?

It calls to mind that at Columbia's Graduate School of Journalism, where her bio says she went, and where I went, an important lesson drilled into us in the classes, that we must put ourselves in the shoes of the person being targeted, being interviewed, and act with some kind of decency and empathy for that as we report stories. Maybe that lesson isn't taught anymore, but I'd be surprised if it wasn't. 

What isn't in the story is what the engineers were actually doing -- were they pushing buttons, reading through code, or making actual decisions about which government programs are full of waste, fraud and inefficiency and worth cutting?

Missing also is that maybe the purpose of DOGE is to put outside eyes into the innards of government, given its inability to control its costs or maintain its civil service neutrality; outsiders that are free of potential conflicts of interest.

All we hear is that the engineers are 'inexperienced' with government, so shiver, they might break it.

The underlying message of that is that government belongs to the deep state and knowledge of its workings is an inner sanctum imperceptible to the eyes of any outsider. Which is what makes me think of her NewsGuard past and its propensity to defend deep state narratives might just have had something to do with why this hit piece was written.

https://www.americanthinker.com/blog/2025/02/ex_newsguard_operative_opens_the_door_to_leftists_doxxing_elon_musk_s_young_doge_software_engineers.html

CT Democrat denigrates DOGE engineers as ‘creepy 22-year-olds’

 By Olivia Murray

As if these sick, Democrat freaks haven’t been the ones to completely monopolize “creepy” with their fetishistic insistence that little boys can become little girls with a scalpel and a pharmacy’s worth of synthetic hormones, that pedophilia is nothing more than another and totally acceptable sexual orientation, and that pornography is an acceptable medium in classrooms, Connecticut senator Chris Murphy has made it a point to call out DOGE’s engineers and analysts as “creepy 22-year-olds” who are perpetuating a “fraud” upon the American people.

The irony totally escaped Murphy as he proudly posted the video below to his website as if he’d said something clever:

(His little monologue wasn’t witty, it just shows how shockingly unaware he really is.)

Suddenly, the grifters in Congress, handing out trillions of dollars (much of which, we’re finding out, is making it back into their own pockets), are very upset at the prospect that their scheme might be exposed, and coming to an end—I mean how many fallacies can one person fit into a two-minute political speech?

Murphy then encourages his colleagues in the Senate to hold President Trump’s cabinet nominations hostage until Elon Musk and his accountability microscope get the heck outta Washington. 

But creepy? Seriously? Did Murphy fail to notice who his party nominated as the presidential candidate in 2020? Is there anyone in Washington creepier than Joe Biden? Does he remember who they nominated for vice president this time around? Tim Walz just screams creepy.

Well, maybe the Podesta brothers or the Clintons or Doug Emhoff—but there’s still the same common denominator there.

And, would warmongering Murphy have a problem with these creepy 22-year-olds if they were conscripted and sent to die in foreign forever wars so he could get rich? Not a chance.

https://www.americanthinker.com/blog/2025/02/ct_democrat_denigrates_doge_engineers_as_creepy_22_year_olds.html

Turns out we have a state-sponsored media after all, except that they didn't tell us

 By Monica Showalter

Up until now, I'd been under the impression that a free and independent press is a must-have for any credible democracy.

Isn't that what groups like, say, Freedom House, have told us for a number of years?

Wasn't a state-controlled press the sort of thing the Soviets, the Chinese, the Cubans, and other communists did to trash civil liberties, along with a lot of petty dictators?

Weren't we Americans supposed to be unlike them -- what with a free, transparent, independent press and all?

Eat your hearts out, Pravda, TASS, RT, Xinhua, Granma, etc.

Turns out we had a state-controlled press, too, and I'm not talking about NPR or Voice of America, which are up front about their funding. Big chunks of the rest of the supposedly independent press were too, except that they went those communist places one better by not telling their readers. They took aid from USAID and became the state-controlled presses, too, and all you had to do was look at their "product." Any questions as to why they were so biased?

According to Ed Morrissey at HotAir:

Now that the US DOGE Service (USDS) ... has begun number-crunching federal outlays, this corrupt arrangement has become much clearer. Beege wrote about Politico's income from its absurdly priced Politico PRO subscriptions, but a new pass through the data shows that both the New York Times and even the BBC had seven-figure income streams from USAID, too:

USAID funding:

New York Times $3.1M
Politico $32M
BBC $3.2M (approximate)

h/t @StormTorx pic.twitter.com/3AKQydP4Oo

— David Procino (@APBIOonly) February 5, 2025

 

The BBC? Why is a state-owned media outlet in the UK receiving American government funding at all? The UK forces British subjects to underwrite the BBC through license fees, which calls the BBC's credibility into question as a watchdog already. American taxpayers shouldn't be forced to participate in that activity, too.

Here's another, far more inscrutable look at this data on the NYT:

When using the upcoming tools to search for media outlets, note that LLCs and PACs are not included in the data. To find relevant results, search for prominent media names, the names of editors or owners, or nonprofits affiliated with the media outlet. Grok or ChatGPT can assist… pic.twitter.com/2MgOZe7dbl

— DataRepublican (small r) (@DataRepublican) February 5, 2025

Morrissey notes that Reuters also took a large sum through a non-news division.

Other reports have noted that Bill Kristol, who mysteriously changed his party line, moving from right to left, also took a lot of USAID cash through intermediary organizations.

When you take the king's penny, you do the king's bidding, right?

A similar dynamic has been seen with NGOs such as Catholic Charities taking large amounts of federal money -- and becoming staunch supporters of the Biden stance on open borders and illegal immigration, promoting it with religious righteousness even though everyone can see that it's the money, honey. The bishop at the National Cathedral who scolded President Trump at his inaugural services also had her snoot in the federal trough for illegal alien projects. She just didn't tell anyone at the time.

Even Freedom House of all places took a lot of USAID cash.

Fact is, USAID's budget has more than doubled since Joe Biden took office, to $42 million for such projects, suggesting that the bankrolling of the media is a typical Biden pay-to-play scheme, where Biden put media outlets on his string in exchange for their total loyalty to him. Morrissey calls it the 'protection racket.'

And as the media took the federal dollars -- through a variety of means, all deniable to outsiders should they become known -- from inflated subscriptions, to donations to newspaper charities, to cash to non-news parts of the operations, the quality of the press ended up getting lower and lower and lower, and the public began to shun it for its bias.

Combine this with the Biden administration's involvement in the censorship rackets, such as the State Department's Global Engagement Center, or the Pentagon's contracts to "disinformation"-detecting groups like NewsGuard that sought to shut down politically disfavored outlets and it's pretty obvious that a grotesque movement to buy out the mainstream press, and crush the independent press was underway from Biden and company, and now DOGE, which exposed the Twitter files, has managed to use its formidable tech skills to expose and end the clearly illegal, illegitimate and unsavory assault on the First Amendment by Big Government.

As big media outlets took the king's penny and did the king's bidding, they ended up with an unfair advantage in a free marketplace of ideas, while those media outlets who didn't take the king's penny shriveled, not only from not having the positive cash stream from the feds, but beset by groups like NewsGuard, which by coincidence, always gave their highest imprimatur to those media outlets taking the federal cash, and of course, the government-directed censors at pre-Musk Twitter and Facebook. One hand washes the other. One big happy family.

As Ed noted:

Even the most vaunted media orgs covertly sucked at the taxpayer teat while supposedly reporting without fear or favor on the bureaucratic state that supports them. And they did that while the bureaucratic state targeted debate and dissent everywhere else. https://t.co/BU2q3i83Rm

— Ed Morrissey (@EdMorrissey) February 5, 2025

Transparent? Like a black hole.

So no wonder outlets like Ace of Spades has thrown this thought out:

is anyone contemplating a class action lawsuit against the government? At the same time Biden was paying NGOs to drain me of advertising revenue, he was paying millions in taxpayer revenues to friendly propaganda outlets. https://t.co/DF4flUvCW5

— The Reaping Phase (@AceofSpadesHQ) February 5, 2025

The feds under Biden favored some outlets over others and effectively secured their total loyalty, which speaks pretty poorly of the press as an industry, given that none of them ever told their readers. No wonder the public hates them; it's the exact same hatred seen in socialist countries where the state-controlled press dominates.

It's a sorry picture indeed that explains why so many of them are fighting like tigers to take down Musk and his DOGE engineers. But thanks to DOGE, the lid has been blown off, the genie is now out of the bottle, and these outlets are never going to be looked at the same way by the public again.

https://www.americanthinker.com/blog/2025/02/turns_out_we_have_a_state_sponsored_media_after_all_except_that_they_didn_t_tell_us.html

Top 7 Biopharma Licensing Deals of 2024

 

Faced with the encroaching threats of patent expirations and generics, biopharma companies in 2024 invested 33% more in licensing deals, on average, than in 2023 with an eye toward enriching their pipelines with novel and potentially more effective therapies.

Big Pharmas have a looming gap to fill in their pipelines as several of the industry’s most lucrative assets are expected to come off patent. To patch the holes, these companies are turning to biotechs for licensing deals with massive potential earnings.

Merck’s blockbuster cancer therapy Keytruda, for instance, will lose key protections by 2028, while Pfizer and Bristol Myers Squibb are expecting generic erosion for their anticoagulant Eliquis by mid-2028.

Average upfront payments for Phase II lead drugs jumped more than 460% from 2022 to 2024, Alison Labya, a business fundamentals analyst at GlobalData, told BioSpace in an email. Compared with last year’s figures, upfront payments spiked around 30%. Upfront payments, according to Labya, are a “stronger indicator of biopharmaceutical industry activity when evaluating licensing agreements.”

This growth in licensing investments “suggests that biopharmaceutical companies continue to commit large sums of capital to refuel their pipelines for drugs with clinical efficacy and safety data,” Labya added.

The number of licensing deals last year likewise saw a marginal 3.5% increase from 2023, which according to Labya, “signals some revitalization” but remains lower than its recent peak in 2022. This pattern “suggests that the biopharmaceutical industry is still in a recovery phase.”

Big Pharma dominated the top licensing agreements of 2024, the largest of which is a pair of cardiovascular pacts between Novartis and Chinese biotech Shanghai Argo. But smaller biotechs aren’t afraid to make big investments, too, with Sarepta Therapeutics committing nearly $1.1 billion in an RNA interference pact with Arrowhead Pharmaceuticals.

In this article, BioSpace looks at seven of the most notable licensing deals inked in 2024.

Novartis – Shanghai Argo

Date: January 7, 2024

Total disclosed value: $4.165 billion

Novartis opened 2024 with the top deal on this list—a pair of cardiovascular contracts with Chinese biotech Shanghai Argo Biopharmaceutical.

Novartis made an upfront payment of $185 million and Argo is entitled to certain option and milestone payments. Together, the deals could rack up $4.165 billion for Argo, plus tiered royalties. Under the first partnership, Novartis will gain an exclusive license to develop and commercialize an early-stage program for an undisclosed cardiovascular target, as well as the ability to select up to two additional targets for drug discovery. The pharma will then have the option to obtain a worldwide exclusive license for the resulting drug candidates.

Similarly, the second agreement will allow Novartis to exclusively develop a Phase I/IIa cardiovascular program outside the Greater China region.

The Argo deals could help Novartis shore up its cardiovascular franchise amid the encroaching generic threat to its heart failure drug Entresto. Last month, an appeals court ruled against Novartis in its attempt to prevent the entry of a generic version into the U.S. market. Entresto is Novartis’ top asset, bringing in more than $6 billion in net global sales in 2023.

Novartis – PeptiDream

Date: April 30, 2024

Total disclosed value: $2.89 billion

Just a few months after putting more than $4 billion on the line for Argo, Novartis again made a major investment, pledging up to $2.89 billion to expand an existing collaboration with Japan-based PeptiDream.

For $180 million upfront and up to $2.71 billion in development, regulatory and commercial milestones, Novartis will gain access to PeptiDream’s Peptide Discovery Platform System (PDPS) to identify and develop novel macrocyclic peptides. The pharma will be able to select several indications to target, though it has yet to reveal what these are.

Novartis can also conjugate PeptiDream’s peptides with radioligands for therapeutic or diagnostic applications. The pharma’s Lutathera, a radioligand therapy for gastroenteropancreatic neuroendocrine tumors, and Pluvicto, indicated for metastatic castration-resistant prostate cancer, utilize similar technology. Under the expanded agreement, PeptiDream will be eligible for tiered royalties on net sales of any products that reach the market.

Novartis and PeptiDream are longtime collaborators, with their first drug discovery partnership dating back to 2010, according to the April 2024 press release. Novartis licensed the biotech’s PDPS in 2015, followed by a new collaboration in 2019 for the discovery and development of novel macrocyclic peptides against various targets.

Sanofi – Novavax

Date: May 10, 2024

Total disclosed value: $1.2 billion

Despite a stale endemic market, COVID-19 was at the center of one of 2024’s largest licensing deals: a potential $1.2 billion agreement between Sanofi and struggling vaccine developer Novavax.

Novavax provided Sanofi with the sole license to its adjuvanted COVID-19 shot, which the pharma can use alongside its flu vaccines. Sanofi will be solely responsible for developing and marketing combination COVID-19 and flu immunization regimens. Additionally, Sanofi will have a co-exclusive license to co-commercialize Novavax’s adjuvanted COVID-19 shot worldwide, for which the pharma will start booking sales this year.

In return, Sanofi paid Novavax $500 million upfront and promised up to $700 million in development, regulatory and launch milestones. The pharma also took a minority stake in Novavax amounting to less than 5%.

Sanofi’s backing—and money—could prove to be a critical lifeline for Novavax, which for the past few years has struggled to stay afloat. In March 2023, for instance, the company warned investors that it might not have enough funds to continue past February 2024. While Novavax managed to keep itself operational beyond that date, the biotech continues to struggle, with its Q2 2024 earnings falling far short of analyst expectations.

Bristol Myers Squibb – Prime Medicine

Date: September 30, 2024

Total disclosed value: $3.61 billion

In September 2024, Bristol Myers Squibb leaned into one of the hottest areas in biopharma with a potential $3.61 billion gene editing cell therapy partnership with Massachusetts-based Prime Medicine.

BMS made a $55 million upfront payment coupled with a $55 million equity investment to kick off the collaboration. Prime Medicine will be eligible for more than $3.5 billion in milestones—a sum that includes up to $1.4 billion in development milestones and over $2.1 billion in commercialization milestones. BMS has also pledged royalties on net sales of products that arise from the partnership.

Prime Medicine will provide BMS with optimized Prime Editor reagents, which the pharma will use to develop next-generation ex vivo cell therapies for immunology and oncology targets. Prime Medicine will also provide support for gene editing strategy and reagent development.

The Prime partnership could help BMS deepen its pipeline in cell therapy, anchored by its CAR T therapies Breyanzi, indicated for several lymphomas and leukemia, and Abecma, for relapsed or refractory multiple myeloma.

Sarepta Therapeutics – Arrowhead Pharmaceuticals

Date: November 26, 2024

Total disclosed value: $1.075 billion

Large licensing deals aren’t exclusively the territory of Big Pharma. That’s something that Sarepta proved in November 2024, when it put more than $1 billion on the line for an RNA interference pact with Arrowhead Pharmaceuticals.

At the heart of this partnership are four clinical candidates from Arrowhead: ARO-DUX4 for facioscapulohumeral muscular dystrophy, ARO-DM1 for myotonic dystrophy type 1, ARO-MMP7 for idiopathic pulmonary fibrosis and ARO-ATXN2 for spinocerebellar ataxia 2. All four are in Phase I/II development and leverage Arrowhead’s proprietary Targeted RNAi Molecule platform, which allows them to precisely and durably knock down their target genes.

The deal also gives Sarepta access to three preclinical programs, as well as the option to add up to six more muscle, cardiac and/or central nervous system targets for development using Arrowhead’s RNAi technology.

In exchange for these assets, Sarepta made a $550 million upfront payment, alongside a $325 million equity investment in Arrowhead’s common stock. Sarepta also promised to fork over $250 million more, to be paid in $50-million annual installments over five years. Arrowhead is eligible for future milestones and royalties.

Novartis – PTC Therapeutics

Date: December 2, 2024

Total disclosed value: $2.9 billion

Novartis’ third showing on this list is with PTC Therapeutics, a New Jersey biotech focused on rare diseases. The pharma paid $1 billion upfront alongside the promise of up to $1.9 billion in developmental, regulatory and sales milestones to advance PTC518 for Huntington’s disease.

Designed to be taken orally, PTC518 is a small molecule that can cross the blood-brain barrier to reduce the production of the mutant huntingtin protein. In turn, PTC518 is believed to prevent the widespread brain injury and neuronal destruction associated with Huntington’s disease.

PTC518 is currently in the Phase II PIVOT-HD trial, which is expected to wrap up in the first half of this year. Thereafter, Novartis will assume responsibility for the asset through further development and manufacturing.

Earlier in the year, Novartis inked another large neuro deal with Voyager Therapeutics, paying $100 million upfront, including a $20 million equity investment, for access to the biotech’s gene therapies for Huntington’s disease and spinal muscular atrophy. The Voyager agreement involves up to $1.2 billion in milestones.

Bristol Myers Squibb – BioArctic

Date: December 19, 2024

Total disclosed value: $1.35 billion

Like fellow Big Pharma Novartis, BMS leaned into big licensing deals in 2024, with its second entry on this list being a neuro collaboration with BioArctic for $100 million upfront.

The agreement will focus on Alzheimer’s disease, with the partners working on two novel antibodies, BAN1503 and BAN2803, that seek out the more toxic pyroglutamate-modified form of amyloid-beta. The latter asset was designed using BioArctic’s BrainTransporter platform, which makes use of the transferrin receptor to enable penetration of the blood-brain barrier.

BMS will be in charge of the development and commercialization of BAN1503 and BAN2803. Aside from the upfront consideration, BioArctic will also be entitled to up to $1.25 billion in development, regulatory and commercial milestones, plus tiered royalties on global sales of products that make it to the market.

The BioArctic partnership comes after BMS’s $14 billion play to buy Karuna Therapeutics in December 2023 paid off in a major way with the FDA’s approval of Cobenfy in September 2024, marking the first new schizophrenia therapy in more than three decades.

https://www.biospace.com/business/the-top-7-biopharma-licensing-deals-of-2024

Hospitals That Won't Let Patients Go Home

 The International Finance Corp., an arm of the World Bank, spends millions of dollars of taxpayer money to build up private-sector services in the developing world.

But a Bloomberg investigation reveals that several private hospital companies funded by the IFC have kept patients in their care until they can cover their bills or otherwise satisfy the hospital they will be able to pay. This policy can, at times, keep people from going home many days after they are medically ready for discharge. One healthcare company in the Philippines says it's just following the law.

Bloomberg videos, provided by MT Newswires

https://www.marketscreener.com/news/latest/The-Hospitals-That-Won-t-Let-Patients-Go-Home-48972139/